Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: Relationship to anemia and prognosis

European Journal of Haematology

Volumn 75, Issue 6, 2005, Pages 485-491

  Stifter, Gerald ^a,b   Heiss, Simone ^b   Gastl, Günther ^a   Tzankov, Alexander ^b,c   Stauder, Reinhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Microvessel density; Myelodysplastic syndromes; Trephine bone marrow biopsy; Tumor necrosis factor alpha

Indexed keywords

CD34 ANTIGEN; GLYCOPHORIN C; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROPOIESIS; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PREMATURITY; PRIORITY JOURNAL; PROGNOSIS; STEM CELL;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOPSY; BONE MARROW; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; ERYTHROID PROGENITOR CELLS; ERYTHROPOIESIS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MICROCIRCULATION; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28044465152     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00551.x     Document Type: Article

References (37)

1. BRUNNING RD, BENNETT JM, FLANDRIN G, MATUTES E, HEAD D, VARDIMAN JW, HARRIS NL. Myelodysplastic syndrome. In: JAFFE ES, HARRIS NL, STEIN H, VARDIMAN JW, eds. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid System. Lyon: IARC Press, 2001:63-73.
2. PARKER JE, MUFTI GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998;101:220-230.
3. SHETTY V, HUSSAINI S, BROADY-ROBINSON L, ALLAMPALLAM K, MUNDLE S, BOROK R, BRODERICK E, MAZZORAN L, ZORAT F, RAZA A. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000;96:1388-1392.
4. RAZA A, MUNDLE S, SHETTY V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996;63:265-278.
5. MUNDLE SD, ALI A, CARTLIDGE JD, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 1999;60:36-47.
6. SAWANOBORI M, YAMAGUCHI S, HASEGAWA M, INOUE M, SUZUKI K, KAMIYAMA R, HIROKAWA K, KITAGAWA M. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003;27:583-591.
7. BELLAMY WT, RICHTER L, FRUTIGER Y, GROGAN TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733.
8. HUSSONG JW, RODGERS GM, SHAMI PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-313.
9. ALBITAR M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol 2001;106:170-176.
10. BRUNNER B, GUNSILIUS E, SCHUMACHER P, ZWIERZINA H, GASTL G, STAUDER R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 2002;11:119-125.
11. DE BONT ES, ROSATI S, JACOBS S, KAMPS WA, VELLENGA E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001;113:296-304.
12. PRUNERI G, BERTOLINI F, SOLIGO D, CARBONI N, CORTELEZZI A, FERRUCCI PF, BUFFA R, LAMBERTENGHI-DELILIERS G, PEZZELLA F. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-1401.
13. VERSTOVSEK S, ESTEY E, MANSHOURI T, GILES FJ, CORTES J, BERAN M, ROGERS A, KEATING M, KANTARJIAN H, ALBITAR M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002;118:151-156.
14. DISTLER JH, HIRTH A, KUROWSKA-STOLARSKA M, GAY RE, GAY S, DISTLER O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;47:149-161.
15. ERBA HP. Recent progress in the treatment of myelodysplastic syndrome in adult patients. Curr Opin Oncol 2003;15:1-9.
16. LANGSTON AA, WALLING R, WINTON EF. Update on myelodysplastic syndromes: new approaches to classification and therapy. Semin Oncol 2004;31:72-79.
17. MUSTO P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 2004;28:325-332.
18. AGUAYO A. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr Hematol Rep 2004;3:184-191.
19. ESTEY EH. Current challenges in therapy of myelodysplastic syndromes. Curr Opin Hematol 2003;10:60-67.
20. STEURER M, SUDMEIER I, STAUDER R, GASTL G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003;121:101-103.
21. KVASNICKA HM, THIELE J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol 2004;19:1245-1260.
22. CHAUDHARY PM, EBY M, JASMIN A, BOOKWALTER A, MURRAY J, HOOD L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997;7:821-830.
23. MACIEJEWSKI J, SELLERI C, ANDERSON S, YOUNG NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183-3190.
24. SATO T, SELLERI C, ANDERSON S, YOUNG NS, MACIEJEWSKI JP. Expression and modulation of cellular receptors for interferon-gamma, tumor necrosis factor and Fas on human bone marrow CD34+ cells. Br J Haematol 1997;97:356-365.
25. GERSUK GM, BECKHAM C, LOKEN MR, KIENER P, ANDERSON JE, FARRAND A, TROUTT AB, LEDBETTER JA, DEEG HJ. A role of tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176-188.
26. ALEXANDRAKIS M, COULOCHERI S, XYLOURI I, GANOTAKIS E, ELIAKIS P, KARKAVITSAS N, ELIOPOULOS GD. Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes. Haematologia (Budap) 1998;29:13-24.
27. ALEXANDRAKIS MG, PASSAM FH, PAPPA CA, DAMILAKIS J, TSIRAKIS G, KANDIDAKI E, PASSAM AM, STATHOPOULOS EN, KYRIAKOU DS. Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. Int J Immunopathol Pharmacol 2005;18:287-295.
28. OGATA K, TAMURA H, YOKOSE N, AN E, DAN K, HAMAGUCHI H, SAKAMAKI H, ONOZAWA Y, CLARK SC, NOMURA T. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes. Br J Haematol 1995;90:15-21.
29. SHETTY V, MUNDLE S, ALVI S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996;20:891-900.
30. HSU H, XIONG J, GOEDDEL DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995;81:495-504.
31. STASI R, BRUNETTI M, BUSSA S, CONFORTI M, MARTIN LS, LA PRESA M, BIANCHI M, PARMA A, PAGANO A. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 1997;19:197-201.
32. DEEG HJ, GOTLIB J, BECKHAM C, DUGAN K, HOLMBERG L, SCHUBERT M, APPELBAUM F, GREENBERG P. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002;16:162-164.
33. PADRO T, RUIZ S, BIEKER R, BURGER H, STEINS M, KIENAST J, BUCHNER T, BERDEL WE, MESTERS RM. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-2644.
34. KORKOLOPOULOU P, APOSTOLIDOU E, PAVLOPOULOS PM, KAVANTZAS N, VYNIOU N, THYMARA I, TERPOS E, PATSOURIS E, YATAGANAS X, DAVARIS P. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 2001;15:1369-1376.
35. BERNARDINI G, RIBATTI D, SPINETTI G, MORBIDELLI L, ZICHE M, SANTONI A, CAPOGROSSI MC, NAPOLITANO M. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003;273:83-101.
36. BELLAMY WT, RICHTER L, SIRJANI D, ROXAS C, GLINSMANN-GIBSON B, FRUTIGER Y, GROGAN TM, LIST AF. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-1434.
37. FUJITA K, ASAMI Y, MURATA E, AKITA M, KANEKO K. Effects of thalidomide, cytochrome P-450 and TNF-alpha on angiogenesis in a three-dimensional collagen gel-culture. Okajimas Folia Anat Jpn 2002;79:101-106.